SCHEDULE: Nantahala Capital Reports 0.06% Stake in Cellectar

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported a 0.06% beneficial ownership stake in Cellectar Biosciences, Inc. as of June 30, 2025.

Summary

• Nantahala Capital Management, LLC, Wilmot B. Harkey, and Daniel Mack collectively reported beneficial ownership of 1,109 shares of Cellectar Biosciences, Inc. common stock.
• This represents 0.06% of the total outstanding shares of Cellectar Biosciences, Inc.
• The beneficial ownership was reported as of June 30, 2025.
• The reporting persons share both voting and dispositive power over all 1,109 shares.
• The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.

Sentiment

Score: 5

Explanation: This is a neutral filing, simply reporting a beneficial ownership stake. It does not contain information that would inherently suggest positive or negative sentiment regarding the company's performance or prospects.

Future Outlook

Not applicable as this filing is a beneficial ownership report and does not contain forward-looking statements or guidance from the issuer.

Industry Context

This filing is a routine disclosure of beneficial ownership by an investment firm and its managing members in a biotechnology company. It does not provide specific insights into broader industry trends or competitive landscape beyond the fact of the investment itself.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant (though small in this case) ownership stake by an investment firm and its principals.

Key Dates

Keywords

Cellectar Biosciences, Nantahala Capital Management, Wilmot B. Harkey, Daniel Mack, Beneficial Ownership, Schedule 13G, Common Stock, Investment Adviser, Biotechnology, Pharmaceuticals